Heuser M, Freeman SD, Ossenkoppele. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753-2767. doi: 10.1182 ...

Myriad Genetics, Inc. (NASDAQ:MYGN) also announced upcoming launches: a commercial Precise MRD test in 2026, an AI-powered Prolaris prostate cancer test with PATHOMIQ, and an expanded MyRisk ...

Precise MRD detected tumor fractions as low as 0.0001% (1 part per million) and showed a clinically meaningful lead time in detecting recurrence compared to imaging.

Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN to co-develop and commercialize minimal residual ...

Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical ...

Adaptive Biotechnologies. Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL. clonoSEQ is the only DLBCL MRD assay available for ...